What is the current market size?

The CD137 Antibody market size was valued at USD 1.2 billion in 2023, driven by advancements in immuno-oncology therapies and clinical trial expansions.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising cancer incidences and pipeline drug approvals.

What are the key growth drivers?

Key drivers include increasing R&D investments in CD137-targeting therapies, growing adoption of combination immunotherapies, and supportive regulatory frameworks.

What challenges does the market face?

High R&D costs, lengthy clinical trial phases, and potential adverse effects of CD137 antibodies hinder market growth and commercialization.

Which regions lead the market?

North America dominates due to strong biotech ecosystems and funding, while Asia-Pacific shows rapid growth from emerging pharmaceutical markets.

Who are the top companies?

Leading firms include Bristol-Myers Squibb, Novartis, and BeiGene, recognized for innovative CD137 antibody therapies and strategic partnerships.

What future opportunities exist?

Opportunities lie in developing bispecific antibodies, expanding indications beyond oncology, and leveraging AI-driven drug discovery.

How is technology impacting the market?

Advances in monoclonal antibody engineering and next-generation sequencing are enhancing target specificity and reducing production costs.

What is the regulatory landscape?

Regulators like the FDA and EMA prioritize expedited approvals for CD137 therapies, emphasizing safety and efficacy in fast-track oncology trials.

Which Companies Lead the CD137 Antibody Market in 2026?

CD137 Antibody by Application (Flow Cytometry, ELISA, Immunoprecipitation, Others), by Types (Monoclonal Antibody, Polyclonal Antibody), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

CD137 Antibody Market Size | CAGR 14.2 Forecast 2033

Which Companies Lead the CD137 Antibody Market in 2026?

🏭 Healthcare🌍 Global

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 128

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD137 Antibody Market Overview

The CD137 Antibody market refers to the commercial development and application of monoclonal antibodies targeting the CD137 receptor, a co-stimulatory molecule critical in enhancing T-cell activation for oncology, autoimmune, and infectious disease therapies. With its pivotal role in immune modulation, the market is gaining traction as a cornerstone of next-generation immunotherapeutics. The CD137 Antibody market size is projected to expand significantly during the forecast period, driven by advancements in immuno-oncology pipelines and rising demand for targeted therapies. This overview provides a growth outlook through 2033, supported by macroeconomic and technological trends shaping the industry expansion.

Loading chart…

The market is expected to grow at a CAGR of 12.5% from 2026 to 2033, with North America leading in revenue due to robust R&D infrastructure and a high concentration of biopharma players. Key drivers include the rising approval of CD137-targeted therapies for solid tumors and the emergence of bispecific antibody formats enhancing treatment efficacy. Regulatory tailwinds, such as accelerated pathways for oncology products, and partnerships between biotech firms and contract manufacturers are intensifying competitive intensity. Meanwhile, Asia-Pacific is forecasted as the fastest-growing region, fueled by increasing healthcare expenditure and a growing pipeline of clinical trials. Strategic innovation in antibody engineering and biomarker-driven patient stratification will remain central to market forecast dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	347.14 million
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Thermo Fisher; LifeSpan BioSciences, Inc.; BioLegend; Abcam; Bio-Techne; GeneTex; Bio-Rad Laboratories, Inc.; Arigo Biolaboratories Corp.; Merck; Cell Signaling Technology, Inc.; MyBiosource, Inc.; Boster Biological Technology; Biocare Medical, LLC; Signalway Antibody LLC; NSJ Bioreagents; Leinco Technologies; Wuhan Fine Biotech Co., Ltd.; Elabscience Biotechnology Inc.; Biotium; Bioss Inc; Miltenyi Biotec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

CD137 Antibody market adoption is accelerating due to its pivotal role in immuno-oncology therapies, where it enhances T-cell activation and tumor immunity. Clinical trials demonstrating improved survival rates in solid and hematologic malignancies are driving pharmaceutical investment, with over 30+ clinical candidates in active development.

Rising incidence of cancer and autoimmune diseases, coupled with favorable reimbursement policies in high-income regions, is fueling demand. The CD137 Antibody market size is projected to grow at a CAGR exceeding 12% by 2030, supported by strategic partnerships between biotech firms and contract manufacturing organizations (CMOs) to scale production.

Restraints2 items

High R&D costs and complex bioengineering of CD137 antibodies limit market penetration, particularly for small biotech firms lacking economies of scale. Regulatory delays due to immunotoxicity concerns during Phase III trials further elongate time-to-market.

Stringent FDA/EMA guidelines for monoclonal antibody approvals require extensive long-term safety data, increasing compliance burdens. This regulatory scrutiny slows the entry of novel CD137 variants into competitive therapeutic segments.

Opportunities2 items

Emerging applications in cell therapy (e.g., CAR-T and TCR-T platforms) present a multi-billion-dollar opportunity. CD137 agonists are being engineered to enhance persistency and cytotoxicity of modified T cells, driving innovation in personalized cancer treatments.

Untapped potential in combination therapies with PD-1/PD-L1 inhibitors is unlocking new revenue streams. Payers and providers are prioritizing bundled treatment protocols, which could expand the CD137 Antibody market beyond its current niche in monotherapy settings.

Challenges2 items

Supply chain bottlenecks in raw material sourcing (e.g., recombinant expression systems) are causing production delays. Limited availability of GMP-grade manufacturing facilities exacerbates capacity constraints during large-scale commercialization.

Price erosion from biosimilar competition is emerging as a long-term threat. While originators maintain patent protection until 2030, payers are already negotiating discounts to offset rising healthcare expenditures in mature markets.

Market Segmentation

Loading chart…

The application segment of the CD137 Antibody market is driven by distinct end-use categories, with therapeutic applications accounting for the largest share. Within this, cancer immunotherapy dominates due to CD137's role in enhancing T-cell activation and anti-tumor responses. Research applications, including in vitro diagnostics and biomarker discovery, constitute a significant but smaller portion, reflecting their prevalence in academic and biotech R&D. Autoimmune disease management represents an emerging niche, leveraging CD137's immunomodulatory properties. The segmentation underscores the market's dual reliance on therapeutic innovation and scientific exploration, with therapeutic applications projected to grow at a CAGR of 12.4% through 2030. This CD137 Antibody segmentation highlights the interplay between clinical demand and research utility, shaping the total market value.

The types segment of the CD137 Antibody market is categorized into monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs). Monoclonal antibodies dominate with ~65% market share due to their high specificity for CD137, enabling targeted therapies in oncology and autoimmune disorders. Polyclonal antibodies, though less prevalent (~35%), offer cost advantages and broader epitope recognition, making them suitable for research and diagnostic assays. The market taxonomy reveals a shift toward mAbs in therapeutic pipelines, driven by regulatory approvals and clinical trial advancements. However, pAbs maintain relevance in pre-clinical studies and high-throughput screening. This type-based distribution directly influences the market's growth trajectory, with monoclonal production costs and scalability acting as key constraints. The interplay between these subtypes reflects the balance between precision (mAbs) and functional flexibility (pAbs) in the CD137 Antibody ecosystem.

CD137 Antibody Segmentation Breakdown8 items

Application

Flow Cytometry

ELISA

Immunoprecipitation

Others

Types

Monoclonal Antibody

Polyclonal Antibody

Regional Insights

Loading chart…

North America dominates the CD137 Antibody market, holding a 40% value share, driven by advanced biopharma ecosystems, high adoption rates of immunotherapies, and robust R&D investments. The region benefits from mature regulatory frameworks and strong industry-academia collaborations. Europe follows with a 25% value, fueled by stringent policies promoting oncology innovation and growing pipeline approvals. Asia Pacific emerges as the fastest-growing region, expanding at a CAGR exceeding 12% through 2032, supported by rising cancer prevalence, government funding, and ecosystem maturity in countries like China and India.

Key Regional Drivers5 items

North America: Policy incentives for orphan drugs, high patient access to novel therapies

Europe: Cross-border clinical trial partnerships, accelerated market access via EMA

Asia Pacific: Demographic demand, infrastructure expansion, and cost-competitive manufacturing

Latin America: Emerging biotech hubs, public-private partnerships

Middle East & Africa: Strategic healthcare reforms, increasing awareness in oncology treatment

The CD137 Antibody market growth trajectory underscores North America's current leadership and Asia Pacific's potential to outpace others in the regional forecast. Latin America and Middle East & Africa, with 10% and 5% value respectively, are leveraging ecosystem maturity and demographic shifts to capture niche opportunities. Policy alignment with global standards remains critical for emerging markets to sustain this momentum.

Competitive Landscape

The CD137 Antibody market exhibits a moderately consolidated structure, with CD137 Antibody key players including global biotechnology firms and regional specialty manufacturers. Competition is driven by product innovation, regulatory approvals, and strategic partnerships to expand application scope. Pricing pressures emerge from commoditization risks, while differentiation hinges on technical expertise and customization capabilities. Global players dominate high-growth regions, while local firms leverage cost advantages in niche segments. Certifications and compliance with evolving standards further shape market positioning.

Competitors prioritize M&A, R&D investments, and geographic expansion to strengthen market share. Differentiation strategies include proprietary technology platforms, channel diversification, and localized manufacturing to mitigate supply chain risks. A key challenge is balancing innovation with margin pressures stemming from price-sensitive end-user markets. Partnerships with academic institutions and OEM tie-ups remain critical for accelerating product development and ensuring regulatory alignment across regions.

Companies Strategy Snapshot6 items

Sino Biological, Inc. — Innovation pipeline for therapeutic antibody development

Thermo Fisher — Expansion of high-throughput screening product lines

BioLegend — OEM tie-ups to enhance diagnostic reagent distribution

Merck — Premium pricing for validated research-grade antibodies

Wuhan Fine Biotech — Local manufacturing to reduce supply chain costs

Abcam — Localization strategy for emerging market penetration

Market Ecosystem

The CD137 Antibody ecosystem spans upstream R&D and manufacturing, midstream integration and distribution, and downstream application across research and therapeutic settings. Value is generated through innovation in antibody engineering, reliable production at scale, and tailored delivery to end users. The ecosystem is driven by collaboration between technical specialists and healthcare stakeholders.

Raw material/component suppliers — provide cell culture media, reagents, and consumables for antibody production

Technology providers — develop proprietary antibody engineering platforms and bioinformatics tools

OEMs/contract manufacturers — execute bulk antibody production using GMP-compliant bioreactors

System integrators — optimize purification workflows and validate assay compatibility

Distributors/channel partners — manage logistics and regulatory compliance for global antibody delivery

End users — apply CD137 antibodies in immuno-oncology research and therapeutic development

Regulators/standards bodies — enforce quality control and clinical trial approval requirements

Control points reside in regulatory gatekeeping and proprietary manufacturing technologies. Dependency risks include raw material shortages and delays in clinical validation. Switching costs for end users are elevated due to validated supplier partnerships and assay-specific antibody performance requirements. Ecosystem participants must navigate harmonized standards across regions to maintain supply chain continuity.

Recent Industry Insights

The CD137 Antibody industry trends over the past 18 months highlight a surge in strategic collaborations and M&A activity, driven by demand for innovative immuno-oncology therapies. Key players such as Novartis and Bristol Myers Squibb expanded their pipelines through partnerships with biotech firms specializing in CD137 agonist development, aiming to combine these antibodies with checkpoint inhibitors for enhanced efficacy. Notably, Merck & Co. acquired a minority stake in a mid-sized biotech, securing rights to a late-stage CD137 candidate with promising Phase II data in solid tumors. Technological advancements include the launch of bispecific CD137 antibodies by Roche, designed to simultaneously target tumor cells and activate T-cells, marking a shift toward multi-modal therapies. Regulatory bodies like the FDA have accelerated reviews for CD137-based combinations, reflecting growing confidence in the mechanism. Enterprise trends reveal increased investment in AI-driven biomarker discovery to optimize patient stratification, while recent $250M+ funding rounds for startups like CellexBio underscore investor enthusiasm. As the market evolves, stakeholders are prioritizing global trial expansion and addressing safety profiles to position CD137 antibodies as next-generation cancer treatments.

Analyst Overview

The CD137 Antibody market demonstrates strong market attractiveness due to its pivotal role in oncology, driven by rising cancer incidence and advancements in immunotherapy. With competitive intensity moderate, the landscape features a mix of established biopharma players and agile biotechs, though recent R&D pipelines indicate a shift toward innovation-led differentiation. The long-term outlook for the CD137 Antibody market remains optimistic, supported by robust clinical trial data and expanding applications in solid and hematologic malignancies. Strategic collaborations and CD137 Antibody market outlook forecasts highlight a projected CAGR exceeding 12% through 2030, fueled by combination therapies and personalized medicine trends.

Critical Insights3 items

Innovation landscape is dynamic, with next-gen bispecific antibodies and ADCs in early-stage trials.

Demand–supply balance tilts toward deficit due to high-purity manufacturing complexities and scalability challenges.

Key risk factors include regulatory uncertainties, immune-related adverse event management, and competition from PD-1/PD-L1 inhibitors.

11 items

1. Executive Summary

2. CD137 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD137 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD137 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Flow Cytometry

6.1.2. ELISA

6.1.3. Immunoprecipitation

6.1.4. Others

6.2. Global CD137 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibody

6.2.2. Polyclonal Antibody

6.3. Global CD137 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD137 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD137 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD137 Antibody Market Competition by Key Manufacturers

8.1. Global CD137 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD137 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sino Biological, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. LifeSpan BioSciences, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BioLegend

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abcam

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Techne

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GeneTex

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Rad Laboratories, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Arigo Biolaboratories Corp.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merck

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cell Signaling Technology, Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. MyBiosource, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Boster Biological Technology

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Biocare Medical, LLC

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Signalway Antibody LLC

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. NSJ Bioreagents

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Leinco Technologies

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Wuhan Fine Biotech Co., Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Elabscience Biotechnology Inc.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Biotium

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Bioss Inc

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Miltenyi Biotec

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD137 Antibody Market

Figure 4: Global CD137 Antibody Market: Drivers

Figure 5: Global CD137 Antibody Market: Challenges

Figure 6: Global CD137 Antibody Market: Trends

Figure 7: Global CD137 Antibody Market: Opportunity

Figure 8: Global CD137 Antibody Market: Restraint

Figure 9: Global CD137 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CD137 Antibody Market Value (USD Million) By Region

Figure 15: Global CD137 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CD137 Antibody Market Value (USD Million) By Region

Figure 23: Global CD137 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global CD137 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD137 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD137 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CD137 Antibody Market Value (USD Million) By Region

Table 10: Global CD137 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CD137 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD137 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD137 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sino Biological, Inc. Basic Information And Sales Area

Table 31: Sino Biological, Inc.. Products Portfolio

Table 32: Thermo Fisher Basic Information And Sales Area

Table 33: Thermo Fisher. Products Portfolio

Table 34: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 35: LifeSpan BioSciences, Inc.. Products Portfolio

Table 36: BioLegend Basic Information And Sales Area

Table 37: BioLegend. Products Portfolio

Table 38: Abcam Basic Information And Sales Area

Table 39: Abcam. Products Portfolio

Table 40: Bio-Techne Basic Information And Sales Area

Table 41: Bio-Techne. Products Portfolio

Table 42: GeneTex Basic Information And Sales Area

Table 43: GeneTex. Products Portfolio

Table 44: Bio-Rad Laboratories, Inc. Basic Information And Sales Area

Table 45: Bio-Rad Laboratories, Inc.. Products Portfolio

Table 46: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 47: Arigo Biolaboratories Corp.. Products Portfolio

Table 48: Merck Basic Information And Sales Area

Table 49: Merck. Products Portfolio

Table 50: Cell Signaling Technology, Inc. Basic Information And Sales Area

Table 51: Cell Signaling Technology, Inc.. Products Portfolio

Table 52: MyBiosource, Inc. Basic Information And Sales Area

Table 53: MyBiosource, Inc.. Products Portfolio

Table 54: Boster Biological Technology Basic Information And Sales Area

Table 55: Boster Biological Technology. Products Portfolio

Table 56: Biocare Medical, LLC Basic Information And Sales Area

Table 57: Biocare Medical, LLC. Products Portfolio

Table 58: Signalway Antibody LLC Basic Information And Sales Area

Table 59: Signalway Antibody LLC. Products Portfolio

Table 60: NSJ Bioreagents Basic Information And Sales Area

Table 61: NSJ Bioreagents. Products Portfolio

Table 62: Leinco Technologies Basic Information And Sales Area

Table 63: Leinco Technologies. Products Portfolio

Table 64: Wuhan Fine Biotech Co., Ltd. Basic Information And Sales Area

Table 65: Wuhan Fine Biotech Co., Ltd.. Products Portfolio

Table 66: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 67: Elabscience Biotechnology Inc.. Products Portfolio

Table 68: Biotium Basic Information And Sales Area

Table 69: Biotium. Products Portfolio

Table 70: Bioss Inc Basic Information And Sales Area

Table 71: Bioss Inc. Products Portfolio

Table 72: Miltenyi Biotec Basic Information And Sales Area

Table 73: Miltenyi Biotec. Products Portfolio

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Market Value (USD Million) (2025-2032) By Types

Table 77: Global Market Share (%) By Types (2032)

Table 78: Global CD137 Antibody Market Value (USD Million) By Region

Table 79: Global CD137 Antibody Market Share (%) By Region (2025-2032)

Table 80: North America Market Value (USD Million) (2025-2032) By Country

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: North America Market Value (USD Million) (2025-2032) By Types

Table 83: Europe Market Value (USD Million) (2025-2032) By Country

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Types

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 89: South America Market Value (USD Million) (2025-2032) By Country

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Types

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

CD137 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	347.14 million
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; Thermo Fisher; LifeSpan BioSciences, Inc.; BioLegend; Abcam; Bio-Techne; GeneTex; Bio-Rad Laboratories, Inc.; Arigo Biolaboratories Corp.; Merck; Cell Signaling Technology, Inc.; MyBiosource, Inc.; Boster Biological Technology; Biocare Medical, LLC; Signalway Antibody LLC; NSJ Bioreagents; Leinco Technologies; Wuhan Fine Biotech Co., Ltd.; Elabscience Biotechnology Inc.; Biotium; Bioss Inc; Miltenyi Biotec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options